Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof

PH12021551238B1Active Publication Date: 2026-08-14REGENERON PHARMACEUTICALS INC
0 Cites 0 Cited by

Patent Information

Application Number
PH12021551238
Authority / Receiving Office
PH · PH
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-05-28
Publication Date
2026-08-14
Estimated Expiration
2041-05-28
Patent Text Reader

Abstract

The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up- regulated or induced targeted immune response is desired and / or therapeutically beneficial.
Need to check novelty before this filing date? Find Prior Art